Sponsors

Launched in 2025, Taiwan Weeks attracted nearly 28,000 participants over nine days, bringing together more than 1,200 institutional participants, over 250 international investor representatives, and leading exchanges and financial institutions from around the world. The strong international response reflected growing confidence in Taiwan's vision as an Asian Asset Management Center.

Building on this momentum, Taiwan Weeks 2026 will present the next stage of Taiwan’s financial development under the theme “From Tech Island to Capital Hub: Where Capital Meets Technology.” The event will highlight how Taiwan is leveraging its technological and industrial strengths to advance financial innovation and strengthen its capital markets.

The program will focus on seven core themes: Global Outlook and International Connectivity, Asian Market Competitiveness, Innovative Fundraising Platforms, Enhancing Corporate Competitiveness, Financial Innovation and Cybersecurity Resilience, Derivatives and Risk Management, and Diverse Investment and Social Inclusion. Together, these themes highlight Taiwan’s commitment to asset management growth, market resilience, sustainability, and financial inclusion.

As a major platform for international financial engagement, Taiwan Weeks brings together exchanges, asset managers, institutional investors, and industry leaders. The event strengthens global connections, presents Taiwan’s achievements in financial innovation and asset management, and supports long-term investment cooperation.

PharmaEssentia Corporation (TWSE : 6446) is a fully integrated global biopharmaceutical company delivering efficacious, safe and cost-effective therapeutic products for the treatment of human diseases while aiming to bring long lasting value to stakeholders.

PharmaEssentia was founded in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading U.S. biotechnology and pharmaceutical companies in order to develop treatments for myeloproliferative neoplasms, hepatitis and other diseases. The company is committed to the improvement of health and quality of life for patients suffering from these diseases.

The Company's world-class cGMP biologics facility in Taichung is certified by the Taiwan Food and Drug Administration (TFDA) and is designed and operated to be compliant with all U.S. FDA and EMA requirements.